Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 45. More products

VENLAFAXINE HCL

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N06AX) — coverage varies; not interchangeable

  • Duloxetine (Cymbalta): general benefit, Not a benefit
  • Mirtazapine (Remeron RD): general benefit, Not a benefit
  • Trazodone (Desyrel): general benefit, Not a benefit
  • Vortioxetine (Trintellix): general benefit
  • Bupropion (Wellbutrin XL): limited Use 315, Not a benefit
  • Desvenlafaxine (Pristiq): not a benefit

17 more in the class list below

ACT Venlafaxine XR · DIN 02304317 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
ACT Venlafaxine XR · DIN 02304317 Manufacturer: Teva Canada Limited; listing date 2008-04-09 Health Canada: Marketed since 2019-03-01 · brand ACT VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

ACT Venlafaxine XR: Formulary list price $0.0913/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78960 · Verify on the e-Formulary ↗ (DIN 02304317)

Source record
DIN 02304317: ACT Venlafaxine XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id TEV Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $0.0913; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02304317 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78960
Interchangeable products
Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Auro-Venlafaxine XR · DIN 02452839 · $0.0913 Effexor XR · DIN 02237279 · $0.0913 M-Venlafaxine XR · DIN 02471280 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 PMSC-Venlafaxine XR · DIN 02521466 · $0.0913 Sandoz Venlafaxine XR · DIN 02310317 · $0.0913 Taro-Venlafaxine XR · DIN 02380072 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02354713 · $0.0913 Venlafaxine XR · DIN 02385929 · $0.0913 Venlafaxine XR · DIN 02489678 · $0.0913 Venlafaxine XR · DIN 02516535 · $0.0913
Shortage status: discontinued (2018-06-30, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02304317
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Venlafaxine XR · DIN 02452839 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Venlafaxine XR · DIN 02452839 Manufacturer: Auro Pharma Inc.; listing date 2016-05-31 Health Canada: Marketed since 2016-03-14 · brand AURO-VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Venlafaxine XR: Formulary list price $0.0913/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93924 · Verify on the e-Formulary ↗ (DIN 02452839)

Source record
DIN 02452839: Auro-Venlafaxine XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id AUR Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $0.0913; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452839 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93924
Interchangeable products
ACT Venlafaxine XR · DIN 02304317 · $0.0913 Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Effexor XR · DIN 02237279 · $0.0913 M-Venlafaxine XR · DIN 02471280 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 PMSC-Venlafaxine XR · DIN 02521466 · $0.0913 Sandoz Venlafaxine XR · DIN 02310317 · $0.0913 Taro-Venlafaxine XR · DIN 02380072 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02354713 · $0.0913 Venlafaxine XR · DIN 02385929 · $0.0913 Venlafaxine XR · DIN 02489678 · $0.0913 Venlafaxine XR · DIN 02516535 · $0.0913
Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452839
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Effexor XR · DIN 02237279 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Effexor XR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Effexor XR · DIN 02237279 Manufacturer: Upjohn Canada ULC; listing date 2000-01-17 Health Canada: Marketed since 2023-08-09 · brand EFFEXOR XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60600 · Verify on the e-Formulary ↗ (DIN 02237279)

Source record
DIN 02237279: Effexor XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id UJC Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $1.1625; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237279 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60600
Interchangeable products
ACT Venlafaxine XR · DIN 02304317 · $0.0913 Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Auro-Venlafaxine XR · DIN 02452839 · $0.0913 M-Venlafaxine XR · DIN 02471280 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 PMSC-Venlafaxine XR · DIN 02521466 · $0.0913 Sandoz Venlafaxine XR · DIN 02310317 · $0.0913 Taro-Venlafaxine XR · DIN 02380072 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02354713 · $0.0913 Venlafaxine XR · DIN 02385929 · $0.0913 Venlafaxine XR · DIN 02489678 · $0.0913 Venlafaxine XR · DIN 02516535 · $0.0913
Shortage status: resolved shortage (ended 2023-12-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237279
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Venlafaxine XR · DIN 02471280 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Venlafaxine XR · DIN 02471280 Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30 Health Canada: Marketed since 2026-03-05 · brand M-VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Venlafaxine XR: Formulary list price $0.0913/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96039 · Verify on the e-Formulary ↗ (DIN 02471280)

Source record
DIN 02471280: M-Venlafaxine XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id MAT Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $0.0913; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471280 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96039
Interchangeable products
ACT Venlafaxine XR · DIN 02304317 · $0.0913 Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Auro-Venlafaxine XR · DIN 02452839 · $0.0913 Effexor XR · DIN 02237279 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 PMSC-Venlafaxine XR · DIN 02521466 · $0.0913 Sandoz Venlafaxine XR · DIN 02310317 · $0.0913 Taro-Venlafaxine XR · DIN 02380072 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02354713 · $0.0913 Venlafaxine XR · DIN 02385929 · $0.0913 Venlafaxine XR · DIN 02489678 · $0.0913 Venlafaxine XR · DIN 02516535 · $0.0913
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471280
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMSC-Venlafaxine XR · DIN 02521466 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMSC-Venlafaxine XR · DIN 02521466 Manufacturer: Pharmascience Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-09-23 · brand PMSC-VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMSC-Venlafaxine XR: Formulary list price $0.0913/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101065 · Verify on the e-Formulary ↗ (DIN 02521466)

Source record
DIN 02521466: PMSC-Venlafaxine XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id PMS Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $0.0913; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02521466 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101065
Interchangeable products
ACT Venlafaxine XR · DIN 02304317 · $0.0913 Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Auro-Venlafaxine XR · DIN 02452839 · $0.0913 Effexor XR · DIN 02237279 · $0.0913 M-Venlafaxine XR · DIN 02471280 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 Sandoz Venlafaxine XR · DIN 02310317 · $0.0913 Taro-Venlafaxine XR · DIN 02380072 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02354713 · $0.0913 Venlafaxine XR · DIN 02385929 · $0.0913 Venlafaxine XR · DIN 02489678 · $0.0913 Venlafaxine XR · DIN 02516535 · $0.0913
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02521466
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Venlafaxine XR · DIN 02310317 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Venlafaxine XR · DIN 02310317 Manufacturer: Sandoz Canada Inc.; listing date 2008-08-28 Health Canada: Marketed since 2020-03-20 · brand SANDOZ VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Venlafaxine XR: Formulary list price $0.0913/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79596 · Verify on the e-Formulary ↗ (DIN 02310317)

Source record
DIN 02310317: Sandoz Venlafaxine XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id SDZ Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $0.0913; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02310317 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79596
Interchangeable products
ACT Venlafaxine XR · DIN 02304317 · $0.0913 Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Auro-Venlafaxine XR · DIN 02452839 · $0.0913 Effexor XR · DIN 02237279 · $0.0913 M-Venlafaxine XR · DIN 02471280 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 PMSC-Venlafaxine XR · DIN 02521466 · $0.0913 Taro-Venlafaxine XR · DIN 02380072 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02354713 · $0.0913 Venlafaxine XR · DIN 02385929 · $0.0913 Venlafaxine XR · DIN 02489678 · $0.0913 Venlafaxine XR · DIN 02516535 · $0.0913
Shortage status: resolved shortage (ended 2020-01-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02310317
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Venlafaxine XR · DIN 02380072 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Venlafaxine XR · DIN 02380072 Manufacturer: Sun Pharma; listing date 2012-04-24 Health Canada: Marketed since 2020-10-16 · brand TARO-VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Venlafaxine XR: Formulary list price $0.0913/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86591 · Verify on the e-Formulary ↗ (DIN 02380072)

Source record
DIN 02380072: Taro-Venlafaxine XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id SPC Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $0.0913; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02380072 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86591
Interchangeable products
ACT Venlafaxine XR · DIN 02304317 · $0.0913 Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Auro-Venlafaxine XR · DIN 02452839 · $0.0913 Effexor XR · DIN 02237279 · $0.0913 M-Venlafaxine XR · DIN 02471280 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 PMSC-Venlafaxine XR · DIN 02521466 · $0.0913 Sandoz Venlafaxine XR · DIN 02310317 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02354713 · $0.0913 Venlafaxine XR · DIN 02385929 · $0.0913 Venlafaxine XR · DIN 02489678 · $0.0913 Venlafaxine XR · DIN 02516535 · $0.0913
Shortage status: active shortage (reported 2026-05-19, estimated to end 2026-12-18, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380072
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Venlafaxine XR · DIN 02354713 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Venlafaxine XR · DIN 02354713 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2023-01-25 · brand VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Venlafaxine XR: Formulary list price $0.0913/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83988 · Verify on the e-Formulary ↗ (DIN 02354713)

Source record
DIN 02354713: Venlafaxine XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id SAI Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $0.0913; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02354713 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83988
Interchangeable products
ACT Venlafaxine XR · DIN 02304317 · $0.0913 Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Auro-Venlafaxine XR · DIN 02452839 · $0.0913 Effexor XR · DIN 02237279 · $0.0913 M-Venlafaxine XR · DIN 02471280 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 PMSC-Venlafaxine XR · DIN 02521466 · $0.0913 Sandoz Venlafaxine XR · DIN 02310317 · $0.0913 Taro-Venlafaxine XR · DIN 02380072 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02385929 · $0.0913 Venlafaxine XR · DIN 02489678 · $0.0913 Venlafaxine XR · DIN 02516535 · $0.0913
Shortage status: resolved shortage (ended 2025-02-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02354713
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Venlafaxine XR · DIN 02385929 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Venlafaxine XR · DIN 02385929 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2018-06-08 · brand VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Venlafaxine XR: Formulary list price $0.0913/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87153 · Verify on the e-Formulary ↗ (DIN 02385929)

Source record
DIN 02385929: Venlafaxine XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id SIV Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $0.0913; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385929 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87153
Interchangeable products
ACT Venlafaxine XR · DIN 02304317 · $0.0913 Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Auro-Venlafaxine XR · DIN 02452839 · $0.0913 Effexor XR · DIN 02237279 · $0.0913 M-Venlafaxine XR · DIN 02471280 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 PMSC-Venlafaxine XR · DIN 02521466 · $0.0913 Sandoz Venlafaxine XR · DIN 02310317 · $0.0913 Taro-Venlafaxine XR · DIN 02380072 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02354713 · $0.0913 Venlafaxine XR · DIN 02489678 · $0.0913 Venlafaxine XR · DIN 02516535 · $0.0913
Shortage status: resolved shortage (ended 2018-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385929
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Venlafaxine XR · DIN 02489678 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Venlafaxine XR · DIN 02489678 Manufacturer: Laboratoire Riva Inc.; listing date 2024-11-29 Health Canada: Marketed since 2019-08-07 · brand VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Venlafaxine XR: Formulary list price $0.0913/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97974 · Verify on the e-Formulary ↗ (DIN 02489678)

Source record
DIN 02489678: Venlafaxine XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id RIA Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $0.0913; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489678 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97974
Interchangeable products
ACT Venlafaxine XR · DIN 02304317 · $0.0913 Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Auro-Venlafaxine XR · DIN 02452839 · $0.0913 Effexor XR · DIN 02237279 · $0.0913 M-Venlafaxine XR · DIN 02471280 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 PMSC-Venlafaxine XR · DIN 02521466 · $0.0913 Sandoz Venlafaxine XR · DIN 02310317 · $0.0913 Taro-Venlafaxine XR · DIN 02380072 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02354713 · $0.0913 Venlafaxine XR · DIN 02385929 · $0.0913 Venlafaxine XR · DIN 02516535 · $0.0913
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489678
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Venlafaxine XR · DIN 02516535 · 37.5mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Venlafaxine XR · DIN 02516535 Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28 Health Canada: Marketed since 2021-12-29 · brand VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 37.5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Venlafaxine XR: Formulary list price $0.0913/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0913 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100588 · Verify on the e-Formulary ↗ (DIN 02516535)

Source record
DIN 02516535: Venlafaxine XR Raw flags: sec3=Y Item: 281604087; group id 474; item number 1193; lccId None; manufacturer id JPC Source form: ER Cap; strength: 37.5mg Recorded listing: General benefit Source prices (unrounded): $0.0913; ministry $0.0913 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02516535 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100588
Interchangeable products
ACT Venlafaxine XR · DIN 02304317 · $0.0913 Apo-Venlafaxine XR · DIN 02331683 · $0.0913 Auro-Venlafaxine XR · DIN 02452839 · $0.0913 Effexor XR · DIN 02237279 · $0.0913 M-Venlafaxine XR · DIN 02471280 · $0.0913 Mint-Venlafaxine XR · DIN 02522977 · $0.0913 PMS-Venlafaxine XR · DIN 02278545 · $0.0913 PMSC-Venlafaxine XR · DIN 02521466 · $0.0913 Sandoz Venlafaxine XR · DIN 02310317 · $0.0913 Taro-Venlafaxine XR · DIN 02380072 · $0.0913 Teva-Venlafaxine XR · DIN 02275023 · $0.0913 Venlafaxine XR · DIN 02354713 · $0.0913 Venlafaxine XR · DIN 02385929 · $0.0913 Venlafaxine XR · DIN 02489678 · $0.0913
Shortage status: resolved shortage (ended 2025-03-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02516535
Shortage record checked 2026-09-13T08:10:21.292534+00:00

ACT Venlafaxine XR · DIN 02304325 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
ACT Venlafaxine XR · DIN 02304325 Manufacturer: Teva Canada Limited; listing date 2008-04-09 Health Canada: Marketed since 2019-03-01 · brand ACT VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

ACT Venlafaxine XR: Formulary list price $0.1825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78961 · Verify on the e-Formulary ↗ (DIN 02304325)

Source record
DIN 02304325: ACT Venlafaxine XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id TEV Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.1825; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02304325 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78961
Interchangeable products
Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Auro-Venlafaxine XR · DIN 02452847 · $0.1825 Effexor XR · DIN 02237280 · $0.1825 M-Venlafaxine XR · DIN 02471299 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 PMSC-Venlafaxine XR · DIN 02521482 · $0.1825 Sandoz Venlafaxine XR · DIN 02310325 · $0.1825 Taro-Venlafaxine XR · DIN 02380080 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02354721 · $0.1825 Venlafaxine XR · DIN 02385937 · $0.1825 Venlafaxine XR · DIN 02489686 · $0.1825 Venlafaxine XR · DIN 02516543 · $0.1825
Shortage status: active shortage (reported 2026-03-10, estimated to end 2026-08-20, last updated 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02304325
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Venlafaxine XR · DIN 02452847 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Venlafaxine XR · DIN 02452847 Manufacturer: Auro Pharma Inc.; listing date 2016-05-31 Health Canada: Marketed since 2016-03-14 · brand AURO-VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Venlafaxine XR: Formulary list price $0.1825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93925 · Verify on the e-Formulary ↗ (DIN 02452847)

Source record
DIN 02452847: Auro-Venlafaxine XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id AUR Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.1825; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452847 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93925
Interchangeable products
ACT Venlafaxine XR · DIN 02304325 · $0.1825 Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Effexor XR · DIN 02237280 · $0.1825 M-Venlafaxine XR · DIN 02471299 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 PMSC-Venlafaxine XR · DIN 02521482 · $0.1825 Sandoz Venlafaxine XR · DIN 02310325 · $0.1825 Taro-Venlafaxine XR · DIN 02380080 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02354721 · $0.1825 Venlafaxine XR · DIN 02385937 · $0.1825 Venlafaxine XR · DIN 02489686 · $0.1825 Venlafaxine XR · DIN 02516543 · $0.1825
Shortage status: resolved shortage (ended 2019-08-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452847
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Effexor XR · DIN 02237280 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Effexor XR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Effexor XR · DIN 02237280 Manufacturer: Upjohn Canada ULC; listing date 2000-01-17 Health Canada: Marketed since 2023-08-09 · brand EFFEXOR XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60601 · Verify on the e-Formulary ↗ (DIN 02237280)

Source record
DIN 02237280: Effexor XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id UJC Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $2.3242; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237280 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60601
Interchangeable products
ACT Venlafaxine XR · DIN 02304325 · $0.1825 Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Auro-Venlafaxine XR · DIN 02452847 · $0.1825 M-Venlafaxine XR · DIN 02471299 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 PMSC-Venlafaxine XR · DIN 02521482 · $0.1825 Sandoz Venlafaxine XR · DIN 02310325 · $0.1825 Taro-Venlafaxine XR · DIN 02380080 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02354721 · $0.1825 Venlafaxine XR · DIN 02385937 · $0.1825 Venlafaxine XR · DIN 02489686 · $0.1825 Venlafaxine XR · DIN 02516543 · $0.1825
Shortage status: resolved shortage (ended 2018-01-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237280
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Venlafaxine XR · DIN 02471299 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Venlafaxine XR · DIN 02471299 Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30 Health Canada: Marketed since 2026-03-05 · brand M-VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Venlafaxine XR: Formulary list price $0.1825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96040 · Verify on the e-Formulary ↗ (DIN 02471299)

Source record
DIN 02471299: M-Venlafaxine XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id MAT Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.1825; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471299 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96040
Interchangeable products
ACT Venlafaxine XR · DIN 02304325 · $0.1825 Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Auro-Venlafaxine XR · DIN 02452847 · $0.1825 Effexor XR · DIN 02237280 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 PMSC-Venlafaxine XR · DIN 02521482 · $0.1825 Sandoz Venlafaxine XR · DIN 02310325 · $0.1825 Taro-Venlafaxine XR · DIN 02380080 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02354721 · $0.1825 Venlafaxine XR · DIN 02385937 · $0.1825 Venlafaxine XR · DIN 02489686 · $0.1825 Venlafaxine XR · DIN 02516543 · $0.1825
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471299
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMSC-Venlafaxine XR · DIN 02521482 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMSC-Venlafaxine XR · DIN 02521482 Manufacturer: Pharmascience Inc.; listing date 2022-10-31 Health Canada: Marketed since 2022-08-30 · brand PMSC-VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMSC-Venlafaxine XR: Formulary list price $0.1825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101067 · Verify on the e-Formulary ↗ (DIN 02521482)

Source record
DIN 02521482: PMSC-Venlafaxine XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id PMS Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.1825; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02521482 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101067
Interchangeable products
ACT Venlafaxine XR · DIN 02304325 · $0.1825 Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Auro-Venlafaxine XR · DIN 02452847 · $0.1825 Effexor XR · DIN 02237280 · $0.1825 M-Venlafaxine XR · DIN 02471299 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 Sandoz Venlafaxine XR · DIN 02310325 · $0.1825 Taro-Venlafaxine XR · DIN 02380080 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02354721 · $0.1825 Venlafaxine XR · DIN 02385937 · $0.1825 Venlafaxine XR · DIN 02489686 · $0.1825 Venlafaxine XR · DIN 02516543 · $0.1825
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02521482
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Venlafaxine XR · DIN 02310325 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Venlafaxine XR · DIN 02310325 Manufacturer: Sandoz Canada Inc.; listing date 2008-08-28 Health Canada: Marketed since 2020-03-20 · brand SANDOZ VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Venlafaxine XR: Formulary list price $0.1825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79597 · Verify on the e-Formulary ↗ (DIN 02310325)

Source record
DIN 02310325: Sandoz Venlafaxine XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id SDZ Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.1825; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02310325 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79597
Interchangeable products
ACT Venlafaxine XR · DIN 02304325 · $0.1825 Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Auro-Venlafaxine XR · DIN 02452847 · $0.1825 Effexor XR · DIN 02237280 · $0.1825 M-Venlafaxine XR · DIN 02471299 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 PMSC-Venlafaxine XR · DIN 02521482 · $0.1825 Taro-Venlafaxine XR · DIN 02380080 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02354721 · $0.1825 Venlafaxine XR · DIN 02385937 · $0.1825 Venlafaxine XR · DIN 02489686 · $0.1825 Venlafaxine XR · DIN 02516543 · $0.1825
Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02310325
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Venlafaxine XR · DIN 02380080 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Venlafaxine XR · DIN 02380080 Manufacturer: Sun Pharma; listing date 2012-04-24 Health Canada: Marketed since 2020-10-16 · brand TARO-VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Venlafaxine XR: Formulary list price $0.1825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86592 · Verify on the e-Formulary ↗ (DIN 02380080)

Source record
DIN 02380080: Taro-Venlafaxine XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id SPC Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.1825; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02380080 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86592
Interchangeable products
ACT Venlafaxine XR · DIN 02304325 · $0.1825 Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Auro-Venlafaxine XR · DIN 02452847 · $0.1825 Effexor XR · DIN 02237280 · $0.1825 M-Venlafaxine XR · DIN 02471299 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 PMSC-Venlafaxine XR · DIN 02521482 · $0.1825 Sandoz Venlafaxine XR · DIN 02310325 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02354721 · $0.1825 Venlafaxine XR · DIN 02385937 · $0.1825 Venlafaxine XR · DIN 02489686 · $0.1825 Venlafaxine XR · DIN 02516543 · $0.1825
Shortage status: active shortage (reported 2026-04-13, estimated to end 2026-09-11, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380080
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Venlafaxine XR · DIN 02354721 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Venlafaxine XR · DIN 02354721 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2023-05-23 · brand VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Venlafaxine XR: Formulary list price $0.1825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83989 · Verify on the e-Formulary ↗ (DIN 02354721)

Source record
DIN 02354721: Venlafaxine XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id SAI Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.1825; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02354721 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83989
Interchangeable products
ACT Venlafaxine XR · DIN 02304325 · $0.1825 Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Auro-Venlafaxine XR · DIN 02452847 · $0.1825 Effexor XR · DIN 02237280 · $0.1825 M-Venlafaxine XR · DIN 02471299 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 PMSC-Venlafaxine XR · DIN 02521482 · $0.1825 Sandoz Venlafaxine XR · DIN 02310325 · $0.1825 Taro-Venlafaxine XR · DIN 02380080 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02385937 · $0.1825 Venlafaxine XR · DIN 02489686 · $0.1825 Venlafaxine XR · DIN 02516543 · $0.1825
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02354721
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Venlafaxine XR · DIN 02385937 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Venlafaxine XR · DIN 02385937 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2018-06-08 · brand VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Venlafaxine XR: Formulary list price $0.1825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87154 · Verify on the e-Formulary ↗ (DIN 02385937)

Source record
DIN 02385937: Venlafaxine XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id SIV Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.1825; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385937 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87154
Interchangeable products
ACT Venlafaxine XR · DIN 02304325 · $0.1825 Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Auro-Venlafaxine XR · DIN 02452847 · $0.1825 Effexor XR · DIN 02237280 · $0.1825 M-Venlafaxine XR · DIN 02471299 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 PMSC-Venlafaxine XR · DIN 02521482 · $0.1825 Sandoz Venlafaxine XR · DIN 02310325 · $0.1825 Taro-Venlafaxine XR · DIN 02380080 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02354721 · $0.1825 Venlafaxine XR · DIN 02489686 · $0.1825 Venlafaxine XR · DIN 02516543 · $0.1825
Shortage status: resolved shortage (ended 2018-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385937
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Venlafaxine XR · DIN 02489686 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Venlafaxine XR · DIN 02489686 Manufacturer: Laboratoire Riva Inc.; listing date 2024-11-29 Health Canada: Marketed since 2019-08-07 · brand VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Venlafaxine XR: Formulary list price $0.1825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97975 · Verify on the e-Formulary ↗ (DIN 02489686)

Source record
DIN 02489686: Venlafaxine XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id RIA Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.1825; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489686 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97975
Interchangeable products
ACT Venlafaxine XR · DIN 02304325 · $0.1825 Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Auro-Venlafaxine XR · DIN 02452847 · $0.1825 Effexor XR · DIN 02237280 · $0.1825 M-Venlafaxine XR · DIN 02471299 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 PMSC-Venlafaxine XR · DIN 02521482 · $0.1825 Sandoz Venlafaxine XR · DIN 02310325 · $0.1825 Taro-Venlafaxine XR · DIN 02380080 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02354721 · $0.1825 Venlafaxine XR · DIN 02385937 · $0.1825 Venlafaxine XR · DIN 02516543 · $0.1825
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489686
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Venlafaxine XR · DIN 02516543 · 75mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Venlafaxine XR · DIN 02516543 Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28 Health Canada: Marketed since 2022-01-13 · brand VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Venlafaxine XR: Formulary list price $0.1825/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1825 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100589 · Verify on the e-Formulary ↗ (DIN 02516543)

Source record
DIN 02516543: Venlafaxine XR Raw flags: sec3=Y Item: 281604088; group id 474; item number 1194; lccId None; manufacturer id JPC Source form: ER Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.1825; ministry $0.1825 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02516543 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100589
Interchangeable products
ACT Venlafaxine XR · DIN 02304325 · $0.1825 Apo-Venlafaxine XR · DIN 02331691 · $0.1825 Auro-Venlafaxine XR · DIN 02452847 · $0.1825 Effexor XR · DIN 02237280 · $0.1825 M-Venlafaxine XR · DIN 02471299 · $0.1825 Mint-Venlafaxine XR · DIN 02522985 · $0.1825 PMS-Venlafaxine XR · DIN 02278553 · $0.1825 PMSC-Venlafaxine XR · DIN 02521482 · $0.1825 Sandoz Venlafaxine XR · DIN 02310325 · $0.1825 Taro-Venlafaxine XR · DIN 02380080 · $0.1825 Teva-Venlafaxine XR · DIN 02275031 · $0.1825 Venlafaxine XR · DIN 02354721 · $0.1825 Venlafaxine XR · DIN 02385937 · $0.1825 Venlafaxine XR · DIN 02489686 · $0.1825
Shortage status: resolved shortage (ended 2026-07-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02516543
Shortage record checked 2026-09-13T08:10:21.292534+00:00

ACT Venlafaxine XR · DIN 02304333 · 150mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
ACT Venlafaxine XR · DIN 02304333 Manufacturer: Teva Canada Limited; listing date 2008-04-09 Health Canada: Marketed since 2019-03-01 · brand ACT VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 150 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

ACT Venlafaxine XR: Formulary list price $0.1927/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1927 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78962 · Verify on the e-Formulary ↗ (DIN 02304333)

Source record
DIN 02304333: ACT Venlafaxine XR Raw flags: sec3=Y Item: 281604089; group id 474; item number 1195; lccId None; manufacturer id TEV Source form: ER Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.1927; ministry $0.1927 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02304333 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78962
Interchangeable products
Apo-Venlafaxine XR · DIN 02331705 · $0.1927 Auro-Venlafaxine XR · DIN 02452855 · $0.1927 Effexor XR · DIN 02237282 · $0.1927 M-Venlafaxine XR · DIN 02471302 · $0.1927 Mint-Venlafaxine XR · DIN 02522993 · $0.1927 PMS-Venlafaxine XR · DIN 02278561 · $0.1927 PMSC-Venlafaxine XR · DIN 02521474 · $0.1927 Sandoz Venlafaxine XR · DIN 02310333 · $0.1927 Taro-Venlafaxine XR · DIN 02380099 · $0.1927 Teva-Venlafaxine XR · DIN 02275058 · $0.1927 Venlafaxine XR · DIN 02354748 · $0.1927 Venlafaxine XR · DIN 02385945 · $0.1927 Venlafaxine XR · DIN 02489694 · $0.1927 Venlafaxine XR · DIN 02516551 · $0.1927
Shortage status: discontinued (2018-06-30, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02304333
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Venlafaxine XR · DIN 02452855 · 150mg · extended release capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Venlafaxine XR · DIN 02452855 Manufacturer: Auro Pharma Inc.; listing date 2016-05-31 Health Canada: Marketed since 2016-03-14 · brand AURO-VENLAFAXINE XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 150 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Venlafaxine XR: Formulary list price $0.1927/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1927 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93926 · Verify on the e-Formulary ↗ (DIN 02452855)

Source record
DIN 02452855: Auro-Venlafaxine XR Raw flags: sec3=Y Item: 281604089; group id 474; item number 1195; lccId None; manufacturer id AUR Source form: ER Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.1927; ministry $0.1927 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452855 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93926
Interchangeable products
ACT Venlafaxine XR · DIN 02304333 · $0.1927 Apo-Venlafaxine XR · DIN 02331705 · $0.1927 Effexor XR · DIN 02237282 · $0.1927 M-Venlafaxine XR · DIN 02471302 · $0.1927 Mint-Venlafaxine XR · DIN 02522993 · $0.1927 PMS-Venlafaxine XR · DIN 02278561 · $0.1927 PMSC-Venlafaxine XR · DIN 02521474 · $0.1927 Sandoz Venlafaxine XR · DIN 02310333 · $0.1927 Taro-Venlafaxine XR · DIN 02380099 · $0.1927 Teva-Venlafaxine XR · DIN 02275058 · $0.1927 Venlafaxine XR · DIN 02354748 · $0.1927 Venlafaxine XR · DIN 02385945 · $0.1927 Venlafaxine XR · DIN 02489694 · $0.1927 Venlafaxine XR · DIN 02516551 · $0.1927
Shortage status: resolved shortage (ended 2024-03-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452855
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab

TRAZODONE HYDROCHLORIDE

· 17 products · Listed, not a benefit (3), General benefit (14) · strengths: 50mg, 100mg, 150mg · Tab

VORTIOXETINE HYDROBROMIDE

· 6 products · General benefit · strengths: 5mg, 10mg, 20mg · Tab

BUPROPION HCL

· 12 products · Limited Use, codes 315 (10), Listed, not a benefit (2) · strengths: 150mg, 300mg, 100mg · ER Tab, Tab

DESVENLAFAXINE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 100mg · ER Tab

VILAZODONE HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 20mg, 40mg · Tab

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: anxiety disorder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ALPRAZOLAM · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) Generalized Anxiety Disorder XANAX and XANAX TS are indicated for the treatment of Generalized Anxiety Disorder (GAD). PM: https://pdf.hres.ca/dpd_pm/00070545.PDF; date not captured; DIN 00548359; fetched 2026-09-10 Product monograph DULOXETINE · Listed, not a benefit (2), General benefit (36) • Generalized Anxiety Disorder pms-DULOXETINE is indicated for the symptomatic relief of anxiety causing clinically significant distress in patients with generalized anxiety disorder (GAD). PM: https://pdf.hres.ca/dpd_pm/00084896.PDF; date 2026-05-29; DIN 02429446; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS EFFEXOR XR (venlafaxine hydrochloride extended release capsules) is indicated for the symptomatic relief of: • Major depressive disorder • Anxiety causing clinically significant distress in patients with generalized anxiety disorder (GAD). Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. • Social anxiety disorder, also known as social phobia. • Panic disorder, with or without agoraphobia, as defined in DSM-IV Long-term use of EFFEXOR XR: The physician who elects to use EFFEXOR XR for extended periods in the treatment of depression, GAD, social anxiety disorder, or panic disorder should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see 4.1 Dosing Considerations; 4.2 Recommended Dose and Dosage Adjustment). 1.1 Pediatrics Pediatrics (< 18 years of age): Health Canada has not authorized an indication for pediatric use (see 7 WARNINGS AND PRECAUTIONS, Psychiatric, Potential Association With Behavioural And Emotional Changes, Including Self-Harm). 1.2 Geriatrics Geriatrics (> 65 years of age): Caution should be exercise… https://pdf.hres.ca/dpd_pm/00073109.PDF PM date: AUG 09, 2023 Source product: EFFEXOR XR; DIN 02237279; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

ACT Venlafaxine XR · DIN 02304317 Shortage status: discontinued (2018-06-30, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02304317

Check this DIN again

Taro-Venlafaxine XR · DIN 02380072 Shortage status: active shortage (reported 2026-05-19, estimated to end 2026-12-18, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380072

Check this DIN again

ACT Venlafaxine XR · DIN 02304325 Shortage status: active shortage (reported 2026-03-10, estimated to end 2026-08-20, last updated 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02304325

Check this DIN again

Sandoz Venlafaxine XR · DIN 02310325 Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02310325

Check this DIN again

Taro-Venlafaxine XR · DIN 02380080 Shortage status: active shortage (reported 2026-04-13, estimated to end 2026-09-11, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380080

Check this DIN again

ACT Venlafaxine XR · DIN 02304333 Shortage status: discontinued (2018-06-30, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02304333

Check this DIN again